Non-Hodgkin Lymphoma, B-cell

32 clinical trials · Condition

Record	Firm	Date
B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021 (NCT05518383)	Federal Research Institute of Pediatric Hematology, Oncology and Immunology	2022-05-25
Immune Response After SARS-CoV-2 (COVID-19) Vaccination in a Context of Non-Hodgkin Lymphoma (NCT05050461)	Versailles Hospital	2021-11-15
Azacytidine, Bendamustine, Piamprizumab in Refractory/Relapsed B-cell Non-Hodgkin's Lymphoma (NCT04897477)	Chinese PLA General Hospital	2021-04-22
Allogeneic CD19 CAR-T Cells for the Treatment of Relapsed/Refractory B-cell Lymphoma (NCT05143112)	Shenzhen University General Hospital	2021-02-05
A Study of Humanized CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell ALL and B-cell NHL (NCT04532268)	Zhejiang University	2020-08-23
Efficacy and Safety of Lenalidomide With or Without Rituximab and Other Drugs in B-cell Non-Hodgkin's Lymphomas (NCT04435743)	Ruijin Hospital	2019-11-01
Acalabrutinib With Rituximab and Lenalidomide in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (NCT04094142)	Seoul National University Hospital	2019-07-09
Treatment of Refractory/Relapsed Non-Hodgkin Lymphoma With CD19-TriCART Cell Therapy (NCT03720496)	Timmune Biotech Inc.	2018-11-01
PK,PD,Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and Oxaliplatin for the Treatment of Patients With Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma (NCT03488251)	Molecular Templates, Inc.	2018-08-20
Treatment of Refractory/Relapsed Non-Hodgkin Lymphoma With TriCAR-T_CD19 (NCT03497533)	Timmune Biotech Inc.	2018-08-03
T-cells Expressing Anti-CD19 CAR in Pediatric and Young Adults With B-cell Malignancies (NCT02772198)	Sheba Medical Center	2016-11-01
CART-19 Immunotherapy in Mantle Cell Lymphoma (NCT02081937)	Chinese PLA General Hospital	2014-03-01

Track Non-Hodgkin Lymphoma, B-cell automatically

Every clearance here is in the API, with alerts when new ones post.